PatenSee

About

Headcount over time

Offices

Q&A

What is PatenSee's primary focus?

PatenSee is a clinical-stage medical device company developing a non-contact monitoring system for the early detection of vascular access stenosis in hemodialysis patients.

When was PatenSee founded and where is its headquarters?

PatenSee was founded in 2019 and is headquartered in Or Yehuda, Israel.

What was PatenSee's most recent funding round?

In February 2025, PatenSee closed a Seed round, raising $2,000,000. Investors included Michigan Rise and Spark Capital.

What is the total amount of funding PatenSee has raised to date?

PatenSee has raised a total of $2,800,000 across its funding rounds.

Has PatenSee received any significant regulatory designations recently?

In September 2025, PatenSee received FDA Breakthrough Device Designation for its non-contact vascular access management system for hemodialysis patients.

Did PatenSee enter into any clinical collaboration agreements recently?

In February 2024, PatenSee and Fresenius Medical Care signed a clinical collaboration agreement.

What technologies does PatenSee utilize in its product?

PatenSee utilizes advanced multi-modal imaging technologies, AI, and machine learning in its device.

Team · 16

Hagay Drori

Founder · VP Research & Development, GM Israel

Paul Neeb

President, CEO and Director

Eileen Ke

Interim President, US

Noam Taichler

CFO

Shir Tomer

Research and Development Engineer

Chen Bar

Algorithms Lead

Carmel Magen

Software Lead and Consultant

Naama Barel

Clinical Operations

Shai Policker

Chairman

Eran Cohen

VP of Business Development

Yael Spielmann

Quality and Regulatory Affairs

Shosh Friedman

Regulatory & Clinical Consultant

Gal Atarot

Interim CTO

Charmaine Lok

Board Chair, Scientific Advisory Board

Allen R. Nissenson

Strategic Advisor

Jeff Wesley

Board Member

Sectors & technology

Highlights

Tags